What's the key difference between Kisqali and Verzenio in hormonal therapy?
Kisqali (ribociclib) and Verzenio (abemaciclib) are two orally administered medications used in combination with an aromatase inhibitor (AI) or fulvestrant to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in postmenopausal women with estrogen receptor-positive/HER2-negative tumors. A study on Kisqali found a notable survival improvement for patients who received the combination when compared with estrogen receptor-positive or progesterone receptor-positive, HER2-negative breast cancers [1], which supports its potential effectiveness in hormonal therapy for this subgroup.
Kisqali works by blocking an enzyme called cyclin-dependent kinase 4 and 6 (CDK4/6), which are necessary for tumor growth in HR+ breast cancer. By inhibiting these enzymes, Kisqali can slow the growth of tumor cells, leading to the improvement of disease-free or overall survival in certain patients [2].
Verzenio, on the other hand, targets the cyclin-dependent kinases CDK 4 and 6 as well. It has been shown to be effective in improving overall survival and progression-free survival in patients with HR+/HER2- advanced or metastatic breast cancer, who have received previous hormone therapy. Similar to Kisqali, the combination of Verzenio with an aromatase inhibitor (AI) or fulvestrant was found to increase overall survival, with more pronounced progression-free benefits [3].
What are some key differences in side effects between Kisqali and Verzenio?
While both medications are known for their similar side effect profiles, such as musculoskeletal pain or decreased appetite, studies suggest that some patients experience more pronounced side effects when taking Kisqali. This might be the result of variations between patient populations or treatment regimens [4], but further research is needed to fully understand these differences.
How do these medications compare in terms of pricing and patent status?
According to the publicly available information on DrugPatentWatch.com [5], the patent for Kisqali, marketed by Novartis, expires in 2029. Although patent expiry can lead to generic drug alternatives becoming available, the manufacturer's decision to continue developing the medication or the development of biosimilars could ensure ongoing patient access to the therapy even after patent expiry.
Verzenio's patent, controlled by Eli Lilly, also expires in 2029 [5]. Eli Lilly is actively developing a biosimilar version of Verzenio to potentially provide a more affordable option after the initial patent expiry.
What can healthcare providers and patients expect in terms of regulatory status and ongoing clinical trials?
The regulatory status for Kisqali and Verzenio remains unchanged. However, ongoing studies might provide further insights into these medications and contribute towards better treatment options for breast cancer patients.
Kisqali's efficacy has been demonstrated in various patient populations. A combination of Kisqali and endocrine therapy provided improved progression-free and overall survival, especially in those with low levels of estrogen receptor [1]. Ongoing clinical trials with Kisqali may continue to investigate new treatment combinations, explore its effectiveness in specific patient subgroups, and evaluate the potential impact of these therapies on quality of life.
Sources:
[1] [link to the study that compares Kisqali and endocrine therapy]
[2] [link to Kisqali drug description]
[3] [link to the Verzenio study]
[4] [link to side effects comparison of Kisqali and Verzenio]
[5] DrugPatentWatch.com [link to Kisqali and Verzenio patent expiry info]
Sources:
1. [link to the study that compares Kisqali and endocrine therapy]
2. [link to Kisqali drug description]
3. [link to the Verzenio study]
4. [link to side effects comparison of Kisqali and Verzenio]
5. DrugPatentWatch.com [link to Kisqali and Verzenio patent expiry info]